Charlotte, NC (PRWEB) September 20, 2013
Countervail Corporation, a biotechnology company developing a broad spectrum medical countermeasure to the toxic effects of organophosphorus based nerve agents and a large class of pesticides, announced today it has been awarded $343,000 of a Fast Track SBIR Phase II Grant from the National Institute of Neurological Disorders and Stroke (NINDS) part of the National Institutes of Health (NIH).
"We are pleased to have successfully completed the performance milestones required in the first phase of the SBIR grant and look forward to success in phase II," said CEO and President, Bill Basinger.
The continued support by NINDS allows Countervail to build on the development completed in Phase I of the SBIR grant for the use of AverTox™ as a pretreatment against supra lethal exposure to organophosphorus based nerve agents.
About Countervail Corporation
Countervail Corporation, formed in 2007, is an early stage US based company focused on the protection of both our military and civilian populations from chemical and biological threats.
The project described in this press release is being supported by Award Number R44NS068049 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.